A Study on Ivonescimab Plus Chemotherapy as Neoadjuvant Therapy for Borderline Resectable Pancreatic Cancer

This study is testing whether combining a new immunotherapy drug called ivonescimab with chemotherapy before surgery can help shrink pancreatic tumors enough to make them removable. It targets patients whose pancreatic cancer is right on the border of being operable. **You may be eligible if...** - You are between 18 and 75 years old - You have been diagnosed with pancreatic cancer confirmed by biopsy or cell sample - Your tumor is classified as "borderline resectable" (meaning it might be possible to remove with surgery) - You have never received any anti-cancer treatment for pancreatic cancer before - You are in reasonably good physical condition and your blood counts are adequate - Your expected survival is at least 3 months **You may NOT be eligible if...** - Your tumor is larger than 6 cm or has invaded nearby digestive tissue - You have visible spread to lymph nodes or other organs - You have already received any chemotherapy, radiation, or other cancer treatments - You are pregnant or breastfeeding - Your organ function (liver, kidneys, blood) does not meet the study's laboratory requirements Talk to your doctor to see if this trial is right for you.